514 related articles for article (PubMed ID: 24041225)
1. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
[TBL] [Abstract][Full Text] [Related]
2. Pathology of Senegalese breast cancers.
Fitzpatrick MB; Rendi MH; Kiviat NB; Toure P; Dem A; Sow PS; Hawes SE; Feng Q; Allison KH
Pan Afr Med J; 2019; 34():67. PubMed ID: 31819783
[TBL] [Abstract][Full Text] [Related]
3. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
4. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
5. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
Zhu X; Ying J; Wang F; Wang J; Yang H
Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
[TBL] [Abstract][Full Text] [Related]
7. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
8. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
11. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
12. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer survival in Soweto, Johannesburg, South Africa: A receptor-defined cohort of women diagnosed from 2009 to 11.
Cubasch H; Dickens C; Joffe M; Duarte R; Murugan N; Tsai Chih M; Moodley K; Sharma V; Ayeni O; Jacobson JS; Neugut AI; McCormack V; Ruff P
Cancer Epidemiol; 2018 Feb; 52():120-127. PubMed ID: 29306221
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of triple-negative tumors in an urban cancer center.
Lund MJ; Butler EN; Bumpers HL; Okoli J; Rizzo M; Hatchett N; Green VL; Brawley OW; Oprea-Ilies GM; Gabram SG
Cancer; 2008 Aug; 113(3):608-15. PubMed ID: 18484596
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.
Runnak MA; Hazha MA; Hemin HA; Wasan AA; Rekawt RM; Michael HD
BMC Womens Health; 2012 Jun; 12():16. PubMed ID: 22727195
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
17. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.
Dickens C; Duarte R; Zietsman A; Cubasch H; Kellett P; Schüz J; Kielkowski D; McCormack V
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2311-21. PubMed ID: 25143359
[TBL] [Abstract][Full Text] [Related]
18. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
